Axial3D Receives FDA Clearance for Axial3D INSIGHT Medical Image Segmentation Platform

Axial3D, a leader in medical segmentation and 3D solutions announced that it is the first to receive FDA clearance for an automated, AI-driven, cloud-based segmentation platform for orthopedic trauma, orthopedic, maxillofacial, and cardiovascular applications. This achievement is the second FDA clearance Axial3D has received for its segmentation platform, INSIGHT, and a significant milestone for the healthcare industry in its embrace of automation and artificial intelligence to personalize patient care. The FDA clearance is expected to provide a major boost towards scaling up production processes particularly by medical device companies.

Latest Insights: How to Get Started with Prompt Engineering in Generative AI Projects

“We congratulate Axial3D on achieving FDA clearance for their segmentation platform, leveraging the power of automation and AI as a key business driver for their continued success in the medical sector.”

Differentiated by its AWS cloud-based infrastructure, AI algorithms and advanced machine learning techniques, Axial3D INSIGHT automates the conversion process of 2D DICOM images such as CT and MRI scans into accurate 3D visualizations, 3D print-ready files, 3D mesh files, or 3D printed anatomical models, made with Stratasys print technology. By automating the traditionally arduous and time-consuming task of manual or semi-manual image segmentation, Axial3D enables healthcare providers and medical device companies to address more applications while saving hours or days per case and reducing capital expenditures.

“Our FDA clearance for Axial3D INSIGHT is a testament to how far Axial3D has come,” stated Dan Crawford, Founder and CSO of Axial3D. “From our humble beginnings as a startup to now being recognized as a leading medical technology company, this achievement showcases our dedication to pushing the boundaries of innovation in healthcare. We are immensely proud of our team’s commitment in delivering exceptional patient care using advanced automation, artificial intelligence, and machine learning technologies.”

By implementing automation and AI into the workflow, Axial3D is equipping healthcare professionals with powerful tools to make it easier and faster to access patient data in 3D and grow their program. More visible patient data in 3D enables surgeons to enhance diagnostic accuracy, treatment planning, and surgical intervention.

Recommended: AiThority Interview with Brigette McInnis-Day, Chief People Officer at UiPath

The Axial INSIGHT platform also allows medical device companies the ability to accelerate their patient-specific programs quickly by being able to process more patient data with the same resources. This 3D data can then be used to design personalized devices and surgical kits that include surgical plans, models, and surgical guides, that can be 3D printed on a variety of printers including Stratasys systems from Digital Anatomy 3D printers to production-scale additive manufacturing systems.

Stratasys Ltd.led an investment round in late 2022 to help advance Axial3D’s technology and to bring a joint solution to market for healthcare providers and medical device manufacturers. “Stratasys is proud to partner with Axial3D in driving innovation and in transforming the healthcare landscape with 3D solutions that help make personalized healthcare at scale possible,” said Stratasys CEO Dr. Yoav Zeif. “We congratulate Axial3D on achieving FDA clearance for their segmentation platform, leveraging the power of automation and AI as a key business driver for their continued success in the medical sector.

 Latest Interview Insights : AiThority Interview with Abhay Parasnis, Founder and CEO at Typeface

[To share your insights with us, please write to sghosh@martechseries.com] 

The post Axial3D Receives FDA Clearance for Axial3D INSIGHT Medical Image Segmentation Platform appeared first on AiThority.

manufacturing
medical
healthcare
diagnostic
device
devices
artificial intelligence
ai
machine learning
fda